Antonietta Ferretti

Antonietta Ferretti

Auto-generated profile, based on publicly available information

Antonietta Ferretti

Affiliation Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario “A. Gemell” IRCCS, Roma, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
FAFrancesco Autore
Francesco Autore
Paolo StratiPaolo Strati
Paolo Strati
IIIdanna Innocenti
Idanna Innocenti
FCFrancesco Corrente
Francesco Corrente
LTLIVIO TRENTIN
LIVIO TRENTIN
LLLuca Laurenti
Luca Laurenti
Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features and outcome in CLL patients with +12 to identify parameters predictive of disease progression; time to treatment; and survival. The study included 487 treatment-naive CLL patients with +12 from 15 academic centers; diagnosed between January 2000 and July 2016; and 816 treatment-naïve patients with absence of Fluorescence In Situ Hybridization (FISH) abnormalities. A cohort of 250 patients with +12 CLL followed at a single US institution was used for external validation. In patients with +12; parameters associated with worse prognosis in the multivariate model were high Lactate DeHydrogenase (LDH) and β-2-microglobulin and unmutated immunoglobulin heavy-chain variable region gene (IGHV). CLL patients with +12 and high LDH levels showed a shorter Progression-Free-Survival (PFS) (30 months vs. 65 months; p < 0.001), Treatment-Free-Survival (TFS) (33 months vs. 69 months; p < 0.001), Overall Survival (OS) (131 months vs. 181 months; p < 0.001) and greater CLL-related mortality (29% vs. 11% at 10 years; p < 0.001) when compared with +12 CLL patients with normal LDH levels. The same differences were observed in the validation cohort. These data suggest that serum LDH levels can predict PFS; TFS; OS and CLL-specific survival in CLL patients with +12.

26 December 2023 in Haemophilia
Verified
Journal Article
Open access
AFArianna Fornari
Arianna Fornari
IAIppazio Cosimo Antonazzo
Ippazio Cosimo Antonazzo
ARAngiola Rocino
Angiola Rocino
DPDaniele Preti
Daniele Preti
AFAnna Fragomeno
Anna Fragomeno
LMLorenzo Giovanni Mantovani
Lorenzo Giovanni Mantovani
Backgroud: A huge amount of data about psychosocial issues of people with haemophilia (PwH) are available; however, these materials are fragmentary and largely outdated, failing to reflect the impact of current treatment strategies.Aim: Describing the influence of illness on psychosocial aspects of adult PwH (≥18 years) and caregivers of children with haemophilia (CPwH) without inhibitors, in Italy.Methods: Surveys (for adult PwH, CPwH and haemophilia specialists) were developed by a multidisciplinary working group and conducted from November 2019 to June 2020.Results: A total of 120 PwH without inhibitors and 79 CPwH completed the survey. Adult patients reported a significant impairment in many psychosocial aspects, including working activities, relations with family members and social relations. Caregivers generally reported better scores in all aspects of the survey. Mobility, Pain and Mental health domains of EQ‐5D were the most frequently impaired in both patients and caregivers, reducing the perceived quality of life. Genetic counselling was an important issue, 53% of CPwH declaring unawareness of their carrier status, as well as the psychological support offered by the reference center, 67.0% of respondents reporting that no psychological support was provided at the time of diagnosis communication.Conclusion: This study provides information about PwH's and CPwH's point of view in the current scenario of continuous innovations in haemophilia treatment and management furthermore, updated insights on psychosocial problems faced by patients and caregivers are reported.

18 March 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
MMMaria Gabriella Mazzucconi
Maria Gabriella Mazzucconi
FRFrancesco Rodeghiero
Francesco Rodeghiero
GAGiuseppe Avvisati
Giuseppe Avvisati
Valerio De StefanoValerio De Stefano
Valerio De Stefano
LGLuigi Gugliotta
Luigi Gugliotta
CSCristina Santoro
Cristina Santoro
A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response [PR], minimal response [MR]) were 44 of 56 (78.57%) in Arm A and 46 of 49 (93.88%) in Arm B at days 42 and 46, respectively (P = 0.0284). Total final responses (at day 180 from initial response) were 26 of 43 (60.47%) in Arm A and 23 of 39 (58.97%) in Arm B (P = 0.8907). Total persistent responses (at 12 months from initial response) were 25 of 31 (80.65%) in Arm A and 20 of 36 (55.56%) in Arm B (P = 0.0292). Seven relapses occurred. Median follow-up was 44.4 months. Overall survival was 100% at 48 months, overall disease-free survival was 81.11% at 48 months from day 180. PDN and pulsed HD-DXM were well tolerated; HD-DXM allows effective initial responses but less long lasting than PDN. This trial was registered at www.clinicaltrials.gov as #NCT00657410.

8 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
CCCristina Capuano
Cristina Capuano
CPChiara Pighi
Chiara Pighi
SBSimone Battella
Simone Battella
FPFabio M Pulcinelli
Fabio M Pulcinelli
CSCristina Santoro
Cristina Santoro
GPGabriella Palmieri
Gabriella Palmieri
In vivo establishment and long-term persistence of a heterogeneous memory or an adaptive NK cell pool represents a functional adaptation to human cytomegalovirus (HCMV) infection in humans. Memory NK cells are commonly identified by lack of the FcεRIγ signalling chain, variably associated to the preferential but not completely overlapping expression of the HLA-E receptor NKG2C and CD57 maturation marker. Although characterized by selective hyperresponsiveness to IgG stimulation, the impact of the CD16/antibody interaction in regulating the establishment/maintenance and size, and in determining the relative abundance of this population, is still under investigation. Memory NK cell subset ex vivo profile and in vitro responsiveness to CD16 stimulation was evaluated in HCMV+ healthy donors and in patients affected by immune thrombocytopenia (ITP), an antibody-mediated autoimmune disease. We identified the FcεRIγ− NKG2C+CD57+ memory NK cell subset, whose abundance is uniquely associated with anti-HCMV antibody levels in healthy seropositive donors, and which is significantly expanded in ITP patients. This fully mature memory subset robustly and selectively expands in vitro in response to mAb-opsonized targets or ITP-derived platelets and displays superior CD16-dependent IFNγ production. Our work identifies opsonizing antibodies as a host-dependent factor that shapes HCMV-driven memory NK cell compartment. We first demonstrate that chronic exposure to auto-antibodies contributes to the establishment/expansion of a highly specialized and unique memory NK cell subset with distinct CD16-dependent functional capabilities. We also identify the specific contribution of the lack of FcεRIγ chain in conferring to NKG2C+CD57+ memory cells a higher responsivity to CD16 engagement.

22 September 2017 in Haemophilia
Verified
Journal Article
Closed access
PDF file
AFA. Ferretti
A. Ferretti
CSC. Santoro
C. Santoro
GFG. Ferrara
G. Ferrara
EBE. Baldacci
E. Baldacci
FBF. Barone
F. Barone
MMM. G. Mazzucconi
M. G. Mazzucconi

17 April 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
MPMarika Porrazzo
Marika Porrazzo
EBErminia Baldacci
Erminia Baldacci
AFAntonietta Ferretti
Antonietta Ferretti
EMEleonora Miulli
Eleonora Miulli
ACAntonio Chistolini
Antonio Chistolini
CSCristina Santoro
Cristina Santoro